Latest Regulatory News

Vitasora Health has completed the first tranche of its $11 million capital raise, positioning the company to fund growth initiatives and reach cash flow breakeven in the second half of fiscal 2026.

Vigorous Resources has launched an unconditional off-market takeover bid for all shares in Rey Resources at a 160% premium, backed by unanimous board support and funding from a major shareholder.

Manuka Resources Ltd has been reinstated to ASX trading following the announcement of a proposed material capital raising, signaling renewed investor interest.

Manuka Resources has launched a fully underwritten A$8 million entitlement offer to fund the restart of its Wonawinta processing plant and advance its 10-year Cobar Basin Production Plan, targeting silver and gold output by early 2026.

ARC Funds Limited has voluntarily suspended trading on the ASX pending a crucial announcement about its proposed capital raising, signaling a pivotal moment for the investment fund.

North Stawell Minerals has extended the closing date of its non-renounceable entitlement offer by two weeks, giving shareholders more time to participate in the $2.1 million capital raise.

Hydralyte USA has placed 39.5 million shortfall shares at $0.01 each, boosting total funds raised under its recent Rights Issue to nearly $559,000. The move strengthens the company’s capital position amid ongoing growth efforts.

L1 Capital and Platinum Asset Management have formalised their merger with a binding agreement, promising continuity for L1 Long Short Fund's management and strategy.

Marquee Resources has identified significant gold anomalies across its 106 km² Yindi Gold Project in Western Australia, backed by a thorough review of historical drilling data. The company plans targeted drilling to validate promising intercepts near major gold operations.

archTIS Limited has successfully raised $7.5 million through a share placement, aiming to fuel its international growth strategy focused on U.S. market expansion, strategic partnerships, and product development.

Platinum Asset Management and L1 Capital have agreed to merge, creating a combined entity managing approximately A$16.5 billion in assets. The deal promises strategic diversification, cost synergies, and significant earnings accretion for shareholders.

Argent BioPharma has begun supplying its EU-GMP cannabinoid API for drug-resistant epilepsy treatment at University Medical Centre Ljubljana, marking a key clinical and regulatory milestone in Europe.